Case Report: an extremely rare case of giant dedifferentiated retroperitoneal liposarcoma
Authors:
Open Access
- 17 March 2025
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1489833
Abstract
Retroperitoneal liposarcoma, especially dedifferentiated liposarcoma (DDL), is a rare tumor type primarily affecting middle-aged and older adults in the retroperitoneum or proximal extremities. This case report highlights an exceptionally large retroperitoneal DDL that had enveloped the entire right kidney and had adhered to nearby tissues. Diagnosing retroperitoneal liposarcoma is challenging due to its asymptomatic nature until it reaches a substantial size. Imaging, particularly contrast-enhanced computed tomography (CECT), play a vital role in diagnosis, staging, and preoperative planning. Surgical resection, with the goal of R0 resection, remains the cornerstone of treatment, albeit this can be challenging due to tumor location. First-line treatment for advanced DDL involves anthracycline-based therapy. Eribulin and pazopanib show promise in second-line treatment. Ongoing clinical trials suggest a shift towards multimodal therapy. This case report reports the largest retroperitoneal liposarcoma and underscores the complexity of managing retroperitoneal DDL.Keywords
This publication has 33 references indexed in Scilit:
- Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statementCancer Treatment Reviews, 2024
- 1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcomaAnnals of Oncology, 2024
- MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionCancer Treatment Reviews, 2023
- Precision guidelines for soft tissue and visceral sarcomas: the evidence, expert experience and ensuring optimal care for rare cancers, a 2021 update from ESMO–EURACAN–GENTURISAnnals of Oncology, 2021
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor PalbociclibJAMA Oncology, 2016
- Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaInternational Journal of Cancer, 2010
- Surgical management of primary retroperitoneal sarcomaBritish Journal of Surgery, 2010
- Retroperitoneal liposarcomas: Follow‐up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomasCancer, 2006
- Retroperitoneal soft tissue sarcomaCancer, 2005
- Surgical management of primary and recurrent retroperitoneal liposarcomaBritish Journal of Surgery, 2005